|
Bruno Montanari is a Principal in the life sciences sector, and joined Atlas Venture in 2004.
He joined Atlas Venture from CDP Capital in Paris where he worked as Investment Manager on deals both in Europe and North America. He began his career as an Investment Banker in the healthcare groups of Deutsche Bank and Merrill Lynch.
He works closely with portfolio companies IDM, Newron Pharmaceuticals, Novexel, and Xytis.
Bruno holds a PharmD from the Université René Descartes and a Masters in Strategic Management from HEC, France.
Investment Sector : Life Sciences
Portfolio Companies :
IDM Pharma Inc., Newron Pharmaceuticals, Novexel, Xytis
Boards :
Xytis
In the News:
Newron Reports Positive Phase II Results for Ralfinamide in Neuropathic Pain
Newron Gains Option to Full Global Rights for Use of Ralfinamide in Pain
Promising Data On Cognitive Effects Of Safinamide In Early Parkinson’s Disease
Newron Announces Presentation of Data on Cognitive Effects in Early Parkinson’s Disease at Movement Disorder Society’s 11th International Congress
Professor Ruggero Fariello Retiring from Newron’s Board
Newron Appoints Carlos de Sousa as New Chief Business Officer | 